# A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

> **NCT02389985** · PHASE1,PHASE2 · TERMINATED · sponsor: **NewLink Genetics Corporation** · enrollment: 30 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** CRLX101
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT02389985
- **Lead sponsor:** NewLink Genetics Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-07
- **Primary completion:** 2018-06-04
- **Final completion:** 2018-10-18
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** Company decision
- **Last updated:** 2020-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02389985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02389985, "A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT02389985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*